If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Acadia Pharmaceuticals (ACAD) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat. This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with pos ...

A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 10% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Acadia Q2 Earnings Beat, Product Sales Drive ...

Acadia Pharmaceuticals Inc. (ACAD) reported second-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate of 16 cents. In the year-ago quarter, the company had recorded earnings of 1 cent per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $242 million, which beat the Zacks Consensus Estimate of $235 million. ACAD’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplazid (pi ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President, Trofinetide Elizabeth Thompson - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 12 ...

○ ACADIA Second Quarter 2024 Earnings Call August 6, 2024 Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Commercial Update Brendan Teehan | Chief Operating Officer, Head of Commercial R&D Update Elizabeth Thompson | Executive Vice President, Head of Research and Development Financial Update Mark Schneyer | Chief Financial Officer Closing Remarks Steve Davis | President and Chief E ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this drugmaker would post earnings of $0.04 per share when it actually produced earnings of $0.10, delivering a surprise of 150%.Over the last four quarters, the comp ...

Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview - Second quarter total net product sales of $242.0 million, up 46% year-over-year SAN DIEGO, CA, August 6, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential ...

The market expects Acadia Pharmaceuticals (ACAD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...